No, can't rush the science. The Doherty COVID study and the exciting PTX-100 and PTX-200 trials just have to run their course. You'd expect, with mounting interest from market players.
But OmniCAR has its own business model, as we've been told. And we're overdue its clear articulation. That's timing the Company
can control.
I liked the 'tip of the iceberg' graphic in the
AGM Presentation showing the incredible host of possible applications and opportunities for OmniCAR - even beyod oncology:
(Click to enlarge)And it's certainly great that we've had so many expressions of interest - reflected in the slide, and reported by our CEO in various recent
Presentations.
But I think we'd all like to hear more about that now!
Particularly plans for commercialising the technology.
SYC has likened OmniCAR to a Ferrari.
Well, as my dear departed Dad would often remind me: ...
The Bird of Time has but a little way to fly - and Lo! the Bird is on the Wing.Our interests are all coincident - management has its Options packages.
Now let's start this thing, and let the suburbs reverberate with the sound. ...And drive it somewhere hugely profitable and worthwhile.
Or at least show us the road map.
